Results of Meeting
Released
Released
Announcement PDF
ASX RELEASE
29 May 2025
Results of General Meeting
Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a
late-stage drug development company focused on delivering new therapies to address
unmet medical needs, advises the outcomes of the General Meeting held on 29 May
2025.
The results of each resolution are as follows:
Resolution
For
For (%)
Against
Against
(%)
Total Votes
Cast
Outcome
1 – Ratification of
Placement Shares
68,810,808
95.50%
3,236,849
4.5%
72,047,657
Carried
2 – Amendment to
Constitution
75,447,458
64.89%
40,829,376
35.11%
116,276,834
Not Carried
(Required
75%)
All discretionary proxies were directed to vote in favour of each resolution.
Based on shareholder feedback following the outcome of Resolution 2, which did not
carry, Paradigm would like to clarify its intention regarding the proposed constitutional
amendment allowing for virtual-only meetings as a part of the amendment.
The Company confirms that:
•
Shareholders would retain the same rights in virtual meetings as they would in
physical or hybrid meetings. This includes the ability to vote, ask questions, and
participate fully in meeting proceedings in accordance with the Corporations Act
and ASX Listing Rules.
•
The amendment was proposed to provide flexibility where a physical or hybrid
meeting may not be feasible (for example, travel restrictions, public health orders,
or emergencies).
•
It is the Company’s intention to continue holding Annual General Meetings (AGMs)
in a hybrid format, thereby retaining an in-person attendance option for
shareholders while enabling broader access through remote participation.
The Paradigm Board would like to thank all shareholders for voting and those that were
able to attend the in-person meeting today.
-EndsAbout Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development
company driven by a purpose to improve patients’ health and quality of life by discovering,
developing, and delivering pharmaceutical therapies. Paradigm’s current focus is
developing iPPS for the treatment of diseases where inflammation plays a major
pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative
properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase
2).
To learn more please visit: https://paradigmbiopharma.com
Approved for release by the Paradigm Board of Directors.
FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com
Share your feedback
Discover